Investigational drug · Phase 2
SKX-16
Also called: Luliconazole 10%
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Onychomycosis of Toenails.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SKX-16"
First trial start
2026
Nov 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKX-16", any sponsor or status.
Conditions studied
As listed on its trial records.
- Onychomycosis of Toenails
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "SKX-16" as an intervention, largest first.
- Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual OnychomycosisPivotal-lookingNot yet recruiting
SATO Pharmaceutical Co., Ltd.Industry
NCT07929844 · 204 participants (planned) · Start Nov 24, 2026 · Primary completion Sep 23, 2028
Drug: SKX-16 (Luliconazole 10% Solution); Vehicle solution · For: Onychomycosis of Toenails
Sites: Los Angeles, California; San Francisco, California; Miami, Florida · 6 sites in all
SATO Pharmaceutical Co., Ltd.Industry
NCT05110638 · 19 participants · Start Sep 22, 2021 · Primary completion May 30, 2022
Drug: SKX-16 (Luliconazole 10% Solution) · For: Onychomycosis of Toenail
Sites: College Station, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.